A B S T R A C T Serological and immunopathological studies of human glomerulonephritis have suggested that alternate pathways of activation of the third component of complement may be important in some forms of glomerulonephritis. We have investigated the role of two alternate pathway proteins, properdin and C3 proactivator, in 22 patients with chronic membranoproliferative glomerulonephritis, 21 patients with systemic lupus erythematosus, 20 patients with acute poststreptococcal glomerulonephritis, and 19 patients with other forms of renal disease. C3 (measured at PA), properdin, and C3 proactivator were assayed by single radial immunodiffusion.
A B S T R A C T Serological and immunopathological studies of human glomerulonephritis have suggested that alternate pathways of activation of the third component of complement may be important in some forms of glomerulonephritis. We have investigated the role of two alternate pathway proteins, properdin and C3 proactivator, in 22 patients with chronic membranoproliferative glomerulonephritis, 21 patients with systemic lupus erythematosus, 20 patients with acute poststreptococcal glomerulonephritis, and 19 patients with other forms of renal disease. C3 (measured at PA), properdin, and C3 proactivator were assayed by single radial immunodiffusion.
In sera with low PA (< 2 SD), mean properdin was most significantly decreased in patients with acute poststreptococcal glomerulonephritis but was also significantly decreased in chronic membranoproliferative glomerulonephritis and in untreated systemic lupus erythematosus. Properdin levels in other renal disease, acute glomerulonephritis, and chronic membranoproliferative glomerulonephritis with normal fiA levels were not significantly different from normal. A positive correlation between PA and properdin levels in individual sera was present in all diseases except systemic lupus erythematosus.
Serum C3 proactivator was markedly decreased in active systemic lupus erythematosus and there was a positive correlation between fi1A and C3 proactivator levels in systemic lupus erythematosus and other renal diseases but not acute poststreptococcal glomerulonephritis.
Properdin in fresh sera from four patients with systemic lupus erythematosus and five with chronic membranoproliferative glomerulonephritis showed increased migration toward the cathode on immunoelectrophoresis, suggesting in vivo change of the properdin molecule.
INTRODUCTION
There is considerable evidence that immunological factors are important in the pathogenesis of some forms of human glomerulonephritis (1) . The effector mechanism of this injury involves in part the complement system. The existence of an alternate pathway of activation of complement which enters the complement sequence at C3 has been demonstrated in vitro by several workers (2) (3) (4) , but the relevance of this pathway in human glomerulonephritis is unknown.
The properdin system as originally described (2) consists of the normal serum protein properdin, magnesium, and two other serum factors: Factor A (hydrazine sensitive) (5) and Factor B (heat labile) (6) . At 370C in the presence of polysaccharides such as zymosan or inulin, the properdin system activates C3. A definite role of the properdin system in human disease has been suggested by the demonstration of reduced serum levels in certain renal diseases (7, 8) and its presence in glomerular deposits in acute poststreptococcal glomerulonephritis (AGN)1 and chronic membranoproliferative glomerulonephritis (CMPGN) associated with hypocomplementemia (9) .
Sandberg, Osler, Shin, and Oliveira (3) demonstrated that the Fc fragment of guinea pig y2 activated 1Abbreviations used in this paper: AGN, acute poststreptococcal glomerulonephritis; C3PA, C3 proactivator; CMPGN, chronic membranoproliferative glomerulonephritis; CoF, anticomplementary factor from cobra venom; GAHP1C, goat antihuman pC; GAHC3PA, goat antihuman C3PA; HSF, hydrazine-sensitive factor; PBS, phosphate-buffered saline; Pc, properdin with increased cathodal migration on electrophoresis; RAHP, rabbit antihuman properdin; SLE, systemic lupus erythematosus. the entire complement sequence, whereas the F (ab')2 fragment of both '4 and 'v2 activated only the terminal complement sequence (C-9). Both t2 and 'Y1 aggregates and F(ab')s fragments have been shown to activate the C3 activator system (10, 11) .
The C3 activator system (4, 12) includes a normal serum protein C3 proactivator (C3PA) which activates C3 in the presence of cations and an activating substance such as cobra venom, polysaccharides, or certain immunoglobulins. Other proteins of the C3PA pathway include a hydrazine-sensitive factor (HSF) which appears to be C3. An activated fragment of C3, C3b (HSFa), and a 3S-a globulin (C3PA convertase) are necessary for activation of C3PA. C3PA has the same antigenic determinants as glycine-rich P-glycoprotein which has recently been reported to have Factor B activity in the properdin system (13) . The relationship of the properdin system to the C3 activator system is presently unclear.
The purpose of this study was to investigate the possible role of the alternate pathway in glomerulonephritis in man, as reflected by changes in serum levels of properdin, C3PA, and PiA.
METHODS

Patients
The patients were seen at the University of Minnesota Hospitals and were divided into four groups.
(a) Chronic membranoproliferative glomerulonephritis (CMPGN) (9 males, 13 females). As previously reported, the diagnosis of CMPGN was based on the clinical picture, the renal pathological findings by light and immunofluorescent microscopy, and the presence of hypocomplementemia at some time during the period of observation (9) . Patients ranged in age from 8 to 35 yr.
(b) Systemic lupus erythematosis (SLE) (5 males, 16 females) was diagnosed by the presence of anti-DNA antibody and LE cells, hypocomplementemia, and systemic symptoms. Fever, arthritis, skin lesions, and abnormal urinary sediment were usually present at some time during the patient's course. Patients ranged in age from 11 to 42 yr.
(c) Acute poststreptococcal glomerulonephritis (AGN) (11 males, 9 females). This included 2 patients with sporadic AGN and 18 patients with epidemic AGN. The clinical and morphologic features of the latter group of patients have been reported previously (14) . Patients ranged in age from 1i to 13 yr.
(d) Other renal diseases (12 males, 7 females). This group included five patients with vasculitis, two with anaphylactoid purpura, two with focal glomerulonephritis, four with proliferative glomerulonephritis (not poststreptococcal), two with membranous glomerulopathy, one with acute tubular necrosis, one with hereditary angioneurotic edema and glomerulonephritis, one with hemolytic-uremic syndrome, and one with end-stage renal disease of unknown etiology. Patients ranged in age from 3 to 21 yr.
Collection of sera
Blood specimens were drawn into serum tubes and allowed to clot at room temperature. Sera were centrifuged, separated, and one aliquot frozen at -70'C within 6 h. A second aliquot (0.3 ml) with sodium azide (0.02%) was tightly sealed and placed in a 370C incubator for 7 days for conversion of all 8,C to #,A (aged sera). The (17) . Antiserum was produced in rabbits by multiple injections of properdin incorporated in com-plete Freund's adjuvant. The specificity of this antiserum has previously been reported. Double diffusion of RAHP against normal human serum yielded a single line and gave no line of identity with GAHC3PA. As previously reported, the RAHP did not react with Clq, C3, or C5; in addition, there was no reaction with isolated C3PA or with C3PA in fresh and aged serum. As previously described, immunoelectrophoresis of fresh normal human serum for properdin produced a single precipitin line migrating in the p-globulin region (18) .
Serial dilutions in phosphate-buffered saline (PBS) (0.15 M sodium chloride and 0.01 M sodium phosphate, pH 7.40) of isolated properdin showed a linear relationship by immunodiffusion between dilutions of 1/2 to 1/8. The reference serum for properdin assay had a concentration of 4.64 ,Ag N per ml of properdin and showed a linear relationship between area and concentration in dilutions of 1/1 to 1/16. For immunodiffusion assay' a 1/2 dilution of the patients' sera which had been stored at -70'C was placed in the wells. The reaction was allowed to proceed for at least 72 h. Precipitin rings were visible at the end of 72 h, but were too faint to be accurately read. The plates were washed in saline with two changes of saline over 48 h, and then soaked in 0.1% tannic acid for 10 min. This rinse was followed by a 10 min wash with 0.2% 8-anilino-1-naphthalenesulfonic acid (ANSA) in 5% acetic acid and 1 min in 5% acetic acid alone (Analytical Chemists, Inc., Palo Alto, Calif. Ag N per ml and seven assays of the same serum at different times revealed a concentration of 35±4 lsg N per ml (1 SD), (SE±1.3).
Immunoelectrophoresis of properdin
Properdin immunoelectrophoresis (18) was performed in 2% Noble agar using the glycine-saline-EDTA (0.002 M) buffer previously described (immunodiffusion assay of #,sC/#,/A properdin and C3PA). Only sera kept at -70'C were examined. A voltage of 4-5 V/cm was measured across the bath supplied by a constant current (50 mA) power supply. Immunoelectrophoresis was performed on human sera placed in 4-mm wells for 4 h at room temperature. RAHP (diluted 1/12) was placed in the troughs and precipitin arcs appeared by 12-18 h with full development after 3 days. Arcs were made more visible by using goat antiserum against rabbit IgG (19) .
In vitro studies
Cobra venom factor effect ont properdin. The anticomplementary factor from cobra venom Naja naja (CoF) was isolated by the method of Mfiller-Eberhard and Fjellstrom properdin, 81C, and C3PA was performed on the serum as previously described (4, 18 RESULTS Properdin. A statistically significant decrease in the serum level of properdin was noted in patients with CMPGN and AGN whose serum level of P1A was decreased more than 2 SD below the mean of normal values (165±-82) (Table I and Appendix). The most striking decrease in serum levels of properdin was seen in patients with AGN (60±24), and CMPGN (72+15); a nonsignificant decrease was observed in sera from patients with SLE (90±25). The level in patients with other renal diseases (124+43) was not significantly different from control values. Comparison of the serum properdin levels in the normal to the low p1A subgroups Fig. 1 ).
Six patients with CMPGN were studied by sequential properdin assays over 3-12 mo (Fig. 2) . Although there was variability, serum properdin levels generally fluc- tuated within 1-2 SD below the mean. In two instances initially low values increased significantly. By contrast, in two patients with nonepidemic AGN, from whom re-AGN peated serum specimens were otbained over a period of 3 mo, serum properdin levels increased rapidly toward the mean during the first 2 mo of illness (Fig. 3) . In epidemic AGN, the serum properdin level was less than 2 SD below the mean in 9/12 patients in whom the date of onset of symptoms was known; all but one of these nine sera were taken within the first 15 days after onset of symptoms. The variation of serum properdin levels in one patient (E. B.) with SLE during azathioprine and prednisone therapy is shown in Fig. 4 . A similar pattern of gradual increase with clinical improvement of the disease was noted in three other patients (L. P., M. T., G. 0.) with SLE (Table III) . One of these patients (L. P.) showed a decline of serum properdin from previously higher levels with clinical exacerbation of the disease (not shown).
The only group of patients receiving immunosuppressive therapy in this study were those with SLE. Six were evaluated before institution of immunosuppressive patients with therapy, one was studied while on low dose, alternate pairopert(d*) day prednisone, and one had been on prednisone daily (74±25) of the untreated SLE patients showed a significant difference from the normal controls but not from the remaining SLE patients in the low f1A and normal ,81A groups. C3PA. A statistically significant reduction in serum C3PA was found in patients with low #1A in CMPGN (33±7) and SLE (27±9). Sera with normal 81A levels also had decreased C3PA levels in CMPGN (31+11) and SLE (33±9). The decreased C3PA levels in CMPGN did not correlate with the level of renal function. In SLE serum C3PA levels 2 SD below the mean were found in six patients. Five of the six had severe lupus nephritis and abnormalities of renal function. A significant decrease in serum C3PA was seen in AGN sera with low ,81A (36±10) but not in sera with normal j81A. No differences were noted when levels in other renal diseases were compared with normal values.
Statistical analysis of the regression lines of O1A vs.
C3PA with one serum from each patient is shown in Table II . The r value derived from analyses of C3PA and P1A levels was significantly different from zero in SLE, other renal diseases, and in the normal population but not for CMPGN and AGN.
A scattergram of C3PA levels in 40 sera from 21 patients with SLE is shown in Fig. 5 C3PA. Longitudinal studies of a patient with SLE over a period of 7 mo shows the effect of immunosuppressive therapy on C3PA levels (Fig. 3) . In this patient, values 2 SD below the mean of serum C3PA rose to normal as 1,A levels increased. Three other patients (G. O., M. T., L. P.) followed 3-9 mo with SLE showed increasing levels of C3PA with clinical improvement (Table III) while on alternate day predisone was 30±5 Ag N per ml and did not differ significantly from levels of the low or normal 813A subgroups. Comparison of the low 11A group to the normal P1A group within each disease category showed no significant difference in serum C3PA levels for CMPGN, SLE, and AGN. Sequential serum C3PA levels examined over 3 mo decreased in one patient with AGN (P. P.) shown in Fig. 3 , but remained in the low range in the second (G. T.). In eight patients with CMPGN who had two or more sera available, serum C3PA levels were lower than the mean but within the range of normal.
Immunoelectrophoresis. 19 normal patients (without renal disease) showed a properdin precipitin arc in the 1-globulin region on immunoelectrophoresis (Fig. 6) .
Four of five patients with SLE evaluated sequentially had sera demonstrating increased cathodal migration of properdin on immunoelectrophoresis (designated Pc) when compared to normal sera (Table II and Fig. 6 ). Patients 1 and 2 had abnormal migration of properdin during periods of activity but normal migration during remission. Sera from patient 5 and one other patient with SLE had properdin levels 2 SD below the mean (55 and 47% of normal); properdin could not be detected in either sera by immunoelectrophoresis. A similar evaluation of sera from four other patients with treated SLE revealed normal properdin migration in two and indeterminate results in two. Sera from 5 of 15 patients with CMPGN also showed increased cathodal migration of properdin. This could not clearly be correlated with the activity of the renal disease. A similar analysis of 10 sera from four patients with sporadic AGN failed to detect any abnomalities. Immunoelectrophoresis of sera from 10 patients (12 sera) with other forms of renal disease have not shown any with cathodal migration of properdin.
After incubation of normal human serum with 1, 2, and 20 U of CoF per ml of sera, increased cathodal migration of properdin was observed on immunoelectrophoresis at all concentrations of CoF (Fig. 7) . Similar changes could be seen after incubation of serum with endotoxin in a concentration of 3.6, 12, and 90 ig per ml of serum. Double diffusion in agarose of normal sera and sera with abnormal properdin migration against RAHP did not show spurring. No antigenic loss could be demonstrated after incubation with CoF or endotoxin. Immunodiffusion assay of properdin showed no change in concentration after incubation with CoF or endotoxin.
Agarose, Ionagar, and barbital buffer (pH 8.6) were found to be less satisfactory for the demonstration of properdin by immunoelectrophoresis. Immunoelectrophoresis for C3PA in aliquots of the above sera showed a new y-migrating arc in addition to the P-arc noted in control sera. Immunoelectrophoresis for #,3C/131A dem-onstrated the appearance of a new arc more anodal to the fl-migrating arc for A1C.
DISCUSSION
The significance of an alternate complement pathway in human disease, particularly immune-related glomerulonephritis, is unknown. These studies have attempted to define the role of two components in this pathway, properdin and C3PA, in patients who are known to have alterations in the serum level of complement or its components and immunopathologic evidence of complementmediated glomerular injury. It is recognized that the precise relationship between properdin and the C3 proactivator system has not been defined, and that serum levels of the components of the complement pathways are static values which reflect the net effect of several forces.
A decrease in serum hemolytic complement has been observed in a number of different forms of glomerulonephritis including AGN, CMPGN, SLE, and certain instances of infection and nephritis (21) (22) (23) (24) (25) . Examination of the serum complement components has shown that CMPGN is characterized by relatively normal early components (Cl, C4, C2), and depression of terminal components (C3-C9), whereas in patients with active SLE all components are decreased. In AGN all components with the frequent exception of Clq are decreased early but only C3 is decreased later in the disease. Gewurz et al. noted the similarity of the complement component profile produced by lipopolysaccharides and polysaccharides to that noted in CMPGN and AGN (8) . Participation of the alternate pathway in diffuse glomerular disease associated with hypocomplementemia is suggested by the results of the present study: depression of serum levels of properdin and C3PA, a correlation between the levels of A1C with properdin and/or C3PA in some diseases but not others, and changes in the electrophoretic migration of serum properdin in vivo. The patients with glomerulonephritis have been evaluated on the basis of the serum level of PfA since both properdin and C3PA participate in the activation of C3. This separation is an arbitrary one, and it is recognized that certain values in the normal 81A groups are still different from normal.
Patients with AGN had the lowest levels of serum properdin and showed the closest correlation with serum PA. With two exceptions, all properdin values which were less than 2 SD below the mean were detected in sera drawn within 2 wk of the onset of clinical illness.
In sequential studies in two patients, properdin and fA levels showed a concomitant return to normal. Significant C3PA depression occurred in AGN, but the serum level was less depressed than in CMPGN or SLE. Patients with CMPGN resembled AGN in the significant depres- sion in levels of properdin and C3PA and the positive correlation between fP1A and properdin, but not between PA and C3PA. Unlike AGN, five patients with CMPGN had one or more sera with abnormal migration of properdin on immunoelectrophoresis.
C3PA was most significantly decreased in SLE and increased to normal as the serum P1A level returned to normal in response to immunosuppressive therapy. Four patients studied during periods of hypocomplementemia showed abnormal migration of properdin on immunoelectrophoresis, and in two patients this has become normal with remission of the disease. Serum properdin was not significantly depressed in sera from SLE patients with low p1A, but a significant decrease was present in SLE patients who were not yet on immunosuppressive therapy or who were early in the treatment course.
It is of interest that a positive correlation was shown between #,A and C3PA for SLE and normal sera. Normal sera did not show a positive correlation of #,1A
vs. properdin. The reason for this difference between C3PA and properdin in normal sera is unknown. Similarly, the significance of the positive correlation between PA and both properdin and C3PA in other renal diseases is not known. Cathodal migration of properdin (Pc) was never detected in sera from normal patients or patients with renal disease other than SLE or CMPGN. However, cathodal migration has been demonstrated in aging serum (18) or after incubation with CoF and endotoxin.
Properdin and C3PA in Glomerulonephritis
In SLE and CMPGN, Pc may represent a different form of properdin which has resulted from in vivo activation of the alternate pathway. Since certain antigens may have been lost from the molecule during isolation procedures or may be present in such small concentrations as to be undetectable by immunodiffusion, it is possible that the change in electrophoretic migration occurs without the appearance or disappearance of different antigens recognized by the antiproperdin serum used. A change of some type in the properdin molecule must have occurred to cause the increased cathodal migration, but the nature of this change is unknown. In early AGN, serum properdin was too low to be detected on immunoelectrophoresis but when the concentration of properdin subsequently increased, no abnormality was noted. Evidence against the possibility that changes in serum concentration of properdin resulted in immunoelectrophoretic change include: normal serum properdin levels in patients with abnormal migration (Table III , cases 1-4), absence of cathodal migration with dilution of normal serum, and no change in properdin concentration by immunodiffusion assay after incubation with CoF or endotoxin.
The question of the biologic importance of the alternate pathway of complement activation is unknown. Properdin has been found deposited on glomeruli in CMPGN, AGN, some cases of SLE and in other renal disease (9) . Utilizing the zymosan assay, serum levels of properdin have been noted to be decreased in some forms of renal disease (8) , but the zymosan assay shows a 26% incidence of low titers in normal subjects (7) , and it is probable that this assay is influenced by other proteins besides properdin. The C3PA system has been found to be necessary in the mediation of paroxysmal hemoglobinuria (26), but we have not detected glomerular deposition of C3PA in human glomerulonephritis. Alper has shown that glycine-rich P-glycoprotein functions as Factor B in the properdin system (13) , and he has described one patient with a congenital deficiency of glycine-rich 3-glycoprotein who has decreased C3 and has had a lifelong history of serious infections (27) . This suggests that the alternate pathway may be involved in defense against infection.
The mechanism of activation of the alternate pathway in human glomerulonephritis is unknown. A C3 nephritic factor (C3 Nef) has been described in patients with CMPGN which activated C3 to PiA and a2D in the presence of cofactor and magnesium (28) . C3 nephritic factor is not C3PA but apparently requires C3PA for C3 activation (29 (Table   IV) .
Compared to normal controls mean serum properdin levels were significantly decreased in the low fiA subgroups of patients with CMPGN and AGN; SLE patients with low f1A were not significantly different, but untreated patients with SLE and low PiA were significantly decreased.
Mean serum C3PA levels were significantly decreased in all diseases except the normal PA subgroups of patients with AGN and other renal diseases.
Addendum. Decreased serum levels of Factor B were found in 8 of
